Skip to contentpdufa.bio

PRA-216 (IL-4Rα/TSLP bispecific)

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

PRA-216 (IL-4Rα/TSLP bispecific) is a Bolt Biotherapeutics, Inc. program in asthma, atopic dermatitis, COPD. Its next catalyst is a Readout in Q2 2027.

BOLT catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: Asthma, atopic dermatitis, COPD. Sponsor: Bolt Biotherapeutics, Inc. (BOLT). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q2 2027BOLT

Questions

When is PRA-216 (IL-4Rα/TSLP bispecific)'s next FDA decision or readout?

The next tracked catalyst for PRA-216 (IL-4Rα/TSLP bispecific) is a Readout in Q2 2027.

What happened at PRA-216 (IL-4Rα/TSLP bispecific)'s most recent FDA decision?

No FDA decision for PRA-216 (IL-4Rα/TSLP bispecific) is in our archive yet.

What is PRA-216 (IL-4Rα/TSLP bispecific) used for?

In our records PRA-216 (IL-4Rα/TSLP bispecific) is under review or in development for Asthma, atopic dermatitis, COPD.

Who makes PRA-216 (IL-4Rα/TSLP bispecific)?

Bolt Biotherapeutics, Inc. (BOLT).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.